Since the launch of the Orbitrap Astral system at the 2023 ASMS conference, pivotal developments ranging from increased single-cell sensitivity and resolution to expanded quantitation and throughput have propelled the fields of proteomics, metabolomics, and lipidomics into new territory. The growing wealth of published research is indicative of the scope and depth of investigations enabled by this new technology. This includes over 60 pre-print and peer-reviewed publications ranging from single-cell proteomics to Alzheimer's biomarker identification and many others.
In this article, we take an exclusive look at the latest achievements of the Orbitrap Astral MS system with the expert guidance of Daniel Hermanson, PhD, senior product marketing manager, LSMS chromatography and mass spectrometry at Thermo Fisher Scientific.
Discussion areas include advancements in:
Along with a review of the latest publications and research discoveries.